Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329446 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
NCT00329446 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 800 participants.
The verdict
NCT00329446, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Interventions
- DRUG Quetiapine Fumarate
- DRUG Escitalopram oxylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329446
The ClinicalTrials.gov registry entry for NCT00329446 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quetiapine Fumarate is the first listed.
NCT00329446 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329446 about?
NCT00329446 is a clinical study titled "Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder". The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation wi...
What is the current status of trial NCT00329446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2006-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00329446?
The interventions under investigation include: Quetiapine Fumarate (DRUG), Escitalopram oxylate (DRUG).
Who is sponsoring clinical trial NCT00329446?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.